KellBenx Raises $2.5M

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Startup biotech firm KellBenx today announced it has raised $2.5 million in an initial funding round.

Four investors participated in the round, three undisclosed venture capital groups and an undisclosed angel investor.

"The funds will be used to launch an [institutional review board]-approved clinical trial and build our Long Island laboratory to analyze the data we are producing," Hassan Bennani, CEO of KellBenx, said in a statement.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: factors influencing retrotransposon integration sites, and more.

A bioethicist argues for the responsible use of germline gene editing.

Some breweries are using DNA-based testing to determine whether unwanted bacteria are affecting their beers, The Verge reports.

Standardized N-of-1 trials will be needed to test out personalized medicines, writes Nicholas Schork from the J. Craig Venter Institute at Nature.